Y-mAbs Therapeutics, Inc. (YMAB)
NASDAQ: YMAB · Real-Time Price · USD
6.19
+0.03 (0.49%)
At close: Jan 21, 2025, 4:00 PM
6.25
+0.06 (0.97%)
After-hours: Jan 21, 2025, 4:30 PM EST
Y-mAbs Therapeutics Revenue
Y-mAbs Therapeutics had revenue of $18.46M in the quarter ending September 30, 2024, a decrease of -9.74%. This brings the company's revenue in the last twelve months to $84.55M, down -8.99% year-over-year. In the year 2023, Y-mAbs Therapeutics had annual revenue of $84.82M with 29.96% growth.
Revenue (ttm)
$84.55M
Revenue Growth
-8.99%
P/S Ratio
3.21
Revenue / Employee
$845,530
Employees
100
Market Cap
277.24M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 87.70B |
Merck & Co. | 63.17B |
AbbVie | 55.53B |
AstraZeneca | 51.21B |
Novartis AG | 49.94B |
Thermo Fisher Scientific | 42.37B |
Abbott Laboratories | 41.22B |
YMAB News
- 11 days ago - Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - GlobeNewsWire
- 11 days ago - Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - GlobeNewsWire
- 11 days ago - Y-mAbs Provides Strategic Business Update and 2025 Priorities - GlobeNewsWire
- 4 weeks ago - Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Y-mAbs Presents SADA Platform Preclinical Data and Trial in Progress Posters at the 2024 American Society Hematology (ASH) Annual Meeting - GlobeNewsWire
- 7 weeks ago - Y-mAbs to Participate at Citi's 2024 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Y-mAbs Therapeutics, Inc. (YMAB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Y-mAbs Reports Third Quarter 2024 Financial Results and Recent Corporate Developments - GlobeNewsWire